The clinical data revealed a 45% objective response rate among patients receiving a 6-milligram dose, accompanied by a 93% disease control rate. Even at lower dosages of 4 milligrams and above, the drug maintained a 34% response rate and a 92% disease control rate. Chief Executive Bing Yao emphasized that these outcomes validate the drug’s potential for patients currently facing narrow treatment pathways.
In section Market Quotes
ArriVent BioPharma Stock Climbs on ARR-217 Trial Success
A 9.3% premarket surge greeted ArriVent BioPharma on Monday following early-stage trial results for its experimental gastrointestinal cancer drug. The company reported that its conjugate, ARR-217, demonstrated significant anti-tumor activity in pretreated colorectal cancer patients, signaling a potential breakthrough for those who have exhausted standard therapeutic options.
Developed in collaboration with Lepu Biopharma, the treatment has now moved into Phase 1b dose optimization. Researchers are currently focusing on 5-milligram and 6-milligram tiers, with additional findings expected in 2027.
Comments (0)
No comments yet. Be the first!